Document is current
Any future updates will be listed below
-
Authors
Haake, Markus https://orcid.org/0009-0008-3353-7919
Haack, Beatrice
Schäfer, Tina
Harter, Patrick N.
Mattavelli, Greta
Eiring, Patrick
Vashist, Neha
Wedekink, Florian
Genssler, Sabrina
Fischer, Birgitt
Dahlhoff, Julia
Mokhtari, Fatemeh
Kuzkina, Anastasia
Welters, Marij J. P. https://orcid.org/0000-0002-9809-8266
Benz, Tamara M.
Sorger, Lena https://orcid.org/0000-0002-6959-3823
Thiemann, Vincent
Almanzar, Giovanni
Selle, Martina
Thein, Klara
Späth, Jacob https://orcid.org/0009-0003-0293-6494
Gonzalez, Maria Cecilia
Reitinger, Carmen https://orcid.org/0000-0003-0515-5119
Ipsen-Escobedo, Andrea
Wistuba-Hamprecht, Kilian https://orcid.org/0000-0002-3104-8512
Eichler, Kristin
Filipski, Katharina
Zeiner, Pia S.
Beschorner, Rudi https://orcid.org/0000-0003-1109-915X
Goedemans, Renske
Gogolla, Falk Hagen
Hackl, Hubert https://orcid.org/0000-0003-4055-3841
Rooswinkel, Rogier W.
Thiem, Alexander https://orcid.org/0000-0001-9504-4281
Roche, Paula Romer
Joshi, Hemant https://orcid.org/0000-0001-7151-359X
Pühringer, Dirk
Wöckel, Achim
Diessner, Joachim E.
Rüdiger, Manfred https://orcid.org/0000-0002-1940-0878
Leo, Eugen
Cheng, Phil F. https://orcid.org/0000-0003-2940-006X
Levesque, Mitchell P. https://orcid.org/0000-0001-5902-9420
Goebeler, Matthias https://orcid.org/0000-0001-7095-9848
Sauer, Markus https://orcid.org/0000-0002-1692-3219
Nimmerjahn, Falk https://orcid.org/0000-0002-5418-316X
Schuberth-Wagner, Christine
von Felten, Stefanie https://orcid.org/0000-0002-5264-6394
Mittelbronn, Michel https://orcid.org/0000-0002-2998-052X
Mehling, Matthias
Beilhack, Andreas https://orcid.org/0000-0002-3165-2648
van der Burg, Sjoerd H.
Riedel, Angela
Weide, Benjamin
Dummer, Reinhard https://orcid.org/0000-0002-2279-6906
Wischhusen, Jörg https://orcid.org/0000-0002-0390-4297
-
Funding
Funding for this research was provided by:
Bayerische Forschungsstiftung (AZ-1365-18)
Bundesministerium für Bildung und Forschung (FKZ031A148)
Deutsche Krebshilfe (#109319)
EC | European Regional Development Fund (Center for Personalized Molecular Immunotherapy)
Deutsche Forschungsgemeinschaft (TRR305-B02, #CRC/TR 221, Z-02)
Fonds National de la Recherche Luxembourg (PEARL P16/BM/11192868)
- License Information
-
More Information
Article History
Received: 14 May 2021
Accepted: 9 June 2023
First Online: 20 July 2023
Competing interests
: M.H., T.S., M. Mehling, M. Selle, R.D., B.W., and J.W. are inventors on patents related to GDF-15 as a biomarker and therapeutic target. M.H., T.S., and J.W. are co-founders of the biotech company CatalYm GmbH involved in translating GDF-15-based cancer therapies and diagnostics into the clinics. M.H., T.S., M.R., E.L., and C.S.W. are current or former employees and stock owners of CatalYm. N.V., S.G., M.C.G., K.E., and P.R.R. are current or former employees of CatalYm. R.R. is a partner of Forbion Capital partners who are invested in CatalYm. R.D. has intermittent, project-focused consulting and/or advisory relationships with Novartis, Merck Sharp & Dohme (MSD), Bristol-Myers Squibb (BMS), Roche, Amgen, Takeda, Pierre Fabre, Sun Pharma, Sanofi, Catalym, Second Genome, Regeneron, Alligator, T3 Pharma, MaxiVAX SA and touchIME outside the submitted work. A.B. is scientific cofounder and advisor of Aamuthera Biotech GmbH and DualYX NV that are not related to this work. K.W.H., H.H., F.N., R.D., and J.W. have received research funding via Catalym GmbH. Other authors declare no competing interests in this work.
